Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Multiple Sclerosis: Myeloperoxidase Immunoradiology Improves Detection of Acute and Chronic Disease in Experimental Model.
Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod.
[Sexuality of men with neurologic disorders].
Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study.
Corticosteroids provoke acute endothelial injury - an ideal ground for thrombosis in multiple sclerosis.
Analysis of the Paired TCR α- and β-chains of Single Human T Cells.
Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology.
Multiple sclerosis relapses and depression.
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US.
Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis virus-induced demyelinating disease.
Strategies for myelin regeneration: lessons learned from development.
Added benefit of fampridine is not proven
1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis.
Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS
ICV-transplanted human glial precursor cells are short-lived yet exert immunomodulatory effects in mice with EAE.
The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials.
Granzyme B-Induced Neurotoxicity Is Mediated via Activation of PAR-1 Receptor and Kv1.3 Channel.
Preparation of Rat Oligodendrocyte Progenitor Cultures and Quantification of Oligodendrogenesis Using Dual-infrared Fluorescence Scanning.
17β-trenbolone, an anabolic-androgenic steroid as well as an environmental hormone, contributes to neurodegeneration.
Laquinimod CHMP/EMA opinion
Young Researchers in Life Sciences Meeting 2012
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Self-Reported Fatigue and Energy Cost During Walking Are Not Related in Patients With Multiple Sclerosis.
Neurologic complications in patients with inflammatory bowel disease: Increasing relevance in the era of biologics.

Pages